Aflac (NYSE:AFL) EVP Sells $839,015.46 in Stock

Aflac Incorporated (NYSE:AFL) EVP Steven Kent Beaver sold 7,387 shares of the firm’s stock in a transaction on Friday, February 20th. The shares were sold at an average price of $113.58, for a total value of $839,015.46. Following the sale, the executive vice president directly owned 40,526 shares of the company’s stock, valued at $4,602,943.08. This represents a 15.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Steven Kent Beaver also recently made the following trade(s):

• On Friday, December 12th, Steven Kent Beaver sold 5,492 shares of Aflac stock. The stock was sold at an average price of $109.53, for a total value of $601,538.76.
• On Friday, December 5th, Steven Kent Beaver sold 3,452 shares of Aflac stock. The shares were sold at an average price of $109.26, for a total value of $377,165.52.

Aflac Stock Performance

Aflac stock opened at $113.90 on Friday. The stock has a 50-day simple moving average of $111.47 and a 200 day simple moving average of $109.92. The stock has a market capitalization of $59.70 billion, a price-to-earnings ratio of 16.56, a P/E/G ratio of 3.68 and a beta of 0.67. The company has a quick ratio of 0.11, a current ratio of 0.11 and a debt-to-equity ratio of 0.29. Aflac Incorporated has a 12-month low of $96.95 and a 12-month high of $119.32.

Aflac (NYSE:AFL) last announced its earnings results on Wednesday, February 4th. The financial services provider reported $1.57 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.69 by ($0.12). The company had revenue of $4.28 billion for the quarter, compared to analyst estimates of $4.45 billion. Aflac had a return on equity of 14.35% and a net margin of 21.24%.Aflac’s revenue for the quarter was down 9.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.57 earnings per share. On average, research analysts anticipate that Aflac Incorporated will post 6.88 earnings per share for the current fiscal year.

Trending Headlines about Aflac

Here are the key news stories impacting Aflac this week:

• Positive Sentiment: Aflac landed a long-term front-of-jersey sponsorship with the NWSL Atlanta expansion team — a 7-year deal that increases local brand visibility in its Georgia home market and supports consumer awareness for supplemental-insurance products. Article Title
• Positive Sentiment: Two recent articles pitching Aflac as a high-yield/AI beneficiary have likely drawn investor interest into the stock as an income and thematic play (coverage boosting retail demand). Article Title
• Neutral Sentiment: Wells Fargo raised its price target from $109 to $118 while keeping an “equal weight” rating — a modest signal of upside but not a fresh buy recommendation. This provides some analyst support but limited conviction. Article Title
• Neutral Sentiment: Recent media pieces comparing Aflac to peers and asking whether to reassess the name highlight mixed fundamentals vs. valuation — useful for context but not new company-specific catalysts. Article Title
• Negative Sentiment: An Aflac EVP, Steven Kent Beaver, sold 7,387 shares (~$839k) in a disclosed SEC filing; insider selling can be interpreted negatively by some investors even though it doesn’t indicate company-wide distress. Article Title
• Negative Sentiment: Recent Q4 results included an EPS miss and year-over-year revenue decline, reminders of operational/headwind risks that limit upside until growth stabilizes. Article Title

Analyst Ratings Changes

AFL has been the subject of a number of recent research reports. Evercore boosted their target price on Aflac from $110.00 to $111.00 and gave the stock an “underperform” rating in a research report on Friday, November 7th. Raymond James Financial reiterated an “outperform” rating and issued a $119.00 price objective (up from $110.00) on shares of Aflac in a research report on Tuesday, December 30th. JPMorgan Chase & Co. upped their target price on shares of Aflac from $101.00 to $105.00 and gave the company a “neutral” rating in a research report on Monday, January 5th. Barclays set a $101.00 target price on shares of Aflac and gave the company an “underweight” rating in a research note on Thursday, January 8th. Finally, Wells Fargo & Company boosted their price target on shares of Aflac from $109.00 to $118.00 and gave the stock an “equal weight” rating in a research note on Wednesday. Three equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Aflac currently has a consensus rating of “Hold” and a consensus target price of $111.73.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. MidFirst Bank bought a new stake in Aflac in the fourth quarter valued at approximately $280,000. Astoria Portfolio Advisors LLC. grew its holdings in shares of Aflac by 10.2% in the 4th quarter. Astoria Portfolio Advisors LLC. now owns 3,814 shares of the financial services provider’s stock valued at $429,000 after buying an additional 353 shares during the period. Pacer Advisors Inc. increased its position in shares of Aflac by 16.2% in the 4th quarter. Pacer Advisors Inc. now owns 45,045 shares of the financial services provider’s stock valued at $4,967,000 after buying an additional 6,295 shares in the last quarter. Kera Capital Partners Inc. acquired a new stake in Aflac during the 4th quarter worth $264,000. Finally, MV Capital Management Inc. acquired a new stake in Aflac during the 4th quarter worth $470,000. Institutional investors own 67.44% of the company’s stock.

About Aflac

Aflac Incorporated (American Family Life Assurance Company of Columbus) is a provider of supplemental insurance products designed to help policyholders manage out-of-pocket health care and living expenses. The company underwrites a range of individual and group policies that typically pay cash benefits directly to insureds when covered events occur, enabling greater financial flexibility for medical treatment, hospital stays, critical illness, and related costs. Aflac’s product mix includes supplemental health insurance, life insurance and other specialty coverages intended to complement primary medical plans.

Founded in the mid-20th century and headquartered in Columbus, Georgia, Aflac distributes its products through a combination of employer-sponsored programs, independent brokers and agents, and direct marketing.